The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for fluticasone furoate/vilanterol (FF/VI) (Relvar Ellipta, ...

LONDON & BRISBANE, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard ...

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...

A new once-daily inhaled corticosteroid and long-acting beta-2-agonist combination inhaler for treatment of both asthma and COPD is available on the NHS from this week. The new inhaler, from ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 20, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese ...